替代途径在HIT免疫复合物补体激活中作用甚微
研究比较经典途径抑制剂(BBK32、C1-INH)、替代途径抑制剂(抗fB或fD抑制剂)及联合抑制剂(sCR1)对HIT免疫复合物补体激活的影响。结果显示经典途径抑制剂和sCR1可阻止补体激活,而替代途径抑制剂无影响。结论提示替代途径对HIT免疫复合物补体激活贡献很小,但需进一步体外和体内研究。
要点
- 经典途径抑制剂BBK32和C1-INH可阻止KKO/HIT免疫复合物诱导的补体激活。
- 替代途径抑制剂抗fB或fD抑制剂不影响KKO/HIT免疫复合物的补体激活。
- 联合抑制剂sCR1可阻止补体激活,但替代途径单独抑制无效。
核心结论
- 这些发现提示替代途径对HIT免疫复合物补体激活贡献很小。
- 需要额外的体外和体内研究来检验这一特性是否为大多数含IgG免疫复合物所共有,或经典途径占优势是否仅限于多价抗原组成的免疫复合物。
研究设计与样本
- 使用IgG单克隆抗体(KKO)和/或患者来源的HIT抗体,在全血或血浆中比较经典途径抑制剂(BBK32和C1酯酶抑制剂[C1-INH])、替代途径抑制剂(抗因子B[fB]或因子D[fD]抑制剂)或经典与替代途径联合抑制剂(可溶性补体受体1[sCR1])的效果。
主要发现
- 经典途径抑制剂BBK32和C1-INH以及联合抑制剂sCR1可阻止KKO/HIT免疫复合物诱导的补体激活,包括C3和C5激活产物的释放、免疫复合物与B细胞的结合以及中性粒细胞激活。
- 替代途径抑制剂fB和fD不影响KKO/HIT免疫复合物引起的补体激活。
- 替代途径抑制对由抗二硝基苯基(DNP)抗体和多价DNP-钥孔戚血蓝蛋白抗原组成的无关免疫复合物的补体激活也无影响。
临床怎么用
- 原文未据此给出推荐。
局限性
- 需要额外的体外和体内研究来检验这一特性是否为大多数含IgG免疫复合物所共有,或经典途径占优势是否仅限于多价抗原组成的免疫复合物。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Anti-platelet factor 4 (PF4)/heparin immune complexes that cause heparin-induced thrombocytopenia (HIT) activate complement via the classical pathway. Previous studies have shown that the alternative pathway of complement substantially amplifies the classical pathway of complement activation through the C3b feedback cycle. OBJECTIVES: These studies sought to examine the contributions of the alternative pathway to complement activation by HIT antibodies. METHODS: Using IgG monoclonal (KKO) and/or patient-derived HIT antibodies, we compared the effects of classical pathway (BBK32 and C1-esterase inhibitor [C1-INH]), alternative pathway (anti-factor B [fB] or factor D [fD] inhibitor) or combined classical and alternative pathway inhibition (soluble complement receptor 1 [sCR1]) in whole blood or plasma. RESULTS: Classical pathway inhibitors BBK32 and C1-INH and the combined classical/alternative pathway inhibitor sCR1 prevented KKO/HIT immune complex-induced complement activation, including release of C3 and C5 activation products, binding of immune complexes to B cells, and neutrophil activation. The alternative pathway inhibitors fB and fD, however, did not affect complement activation by KKO/HIT immune complexes. Similarly, alternative pathway inhibition had no effect on complement activation by unrelated immune complexes consisting of anti-dinitrophenyl (DNP) antibody and the multivalent DNP--keyhole limpet hemocyanin antigen. CONCLUSIONS: Collectively, these findings suggest the alternative pathway contributes little in support of complement activation by HIT immune complexes. Additional in vitro and in vivo studies are required to examine if this property is shared by most IgG-containing immune complexes or if predominance of the classic pathway is limited to immune complexes composed of multivalent antigens.
引用
- Barnes AP, Khandelwal S, Sartoretto S, et al. Minimal role for the alternative pathway in complement activation by HIT immune complexes. J Thromb Haemost. 2022. PMID: 35996342. doi:10.1111/jth.15856
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。